International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Operating Publisher
SciFormat Publishing Inc.
ISNI: 0000 0005 1449 8214

2734 17 Avenue SW,
Calgary, Alberta, T3E0A7,
Canada
+15878858911
editorial-office@sciformat.ca

ARTICLE TITLE	THE ROLE OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN THE PATHOGENESIS, MANAGEMENT AND QUALITY OF LIFE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME – A LITERATURE REVIEW
DOI	https://doi.org/10.31435/ijitss.2(50).2026.5210
RECEIVED	23 February 2026
ACCEPTED	16 April 2026
PUBLISHED	28 April 2026
LICENSE	The article is licensed under a **Creative Commons Attribution 4.0 International License.**

© The author(s) 2026.
This article is published as open access under the Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing the author to retain copyright. The CC BY 4.0 License permits the content to be copied, adapted, displayed, distributed, republished, or reused for any purpose, including adaptation and commercial use, as long as proper attribution is provided.

THE ROLE OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN THE PATHOGENESIS, MANAGEMENT AND QUALITY OF LIFE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME – A LITERATURE REVIEW

Karolina Dąbrowska *(Corresponding Author, Email: karolinadabrowska606@gmail.com)*
Wojewódzki Szpital w Łomży, Łomża, Poland
ORCID ID: 0009-0002-9053-2002

Emilia Lenkiewicz
National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland
ORCID ID: 0009-0001-4822-8157

Alicja Maciejewska
Independent Public Health Care Complex in Pruszków, Pruszków, Poland
ORCID ID: 0009-0009-6903-2434

Monika Stępińska
University Clinical Center of the Medical University of Warsaw, Warsaw, Poland
ORCID ID: 0009-0008-0347-2704

Marta Omiecińska
Międzyleski Specialist Hospital of Warsaw, Warsaw, Poland
ORCID ID: 0009-0002-3134-8141

Maja Kaczor
National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland
ORCID ID: 0009-0001-8218-5429

Weronika Trynkiewicz
Ludwik Rydygier Specialist Hospital, Kraków, Poland
ORCID ID: 0009-0008-2267-7166

Zuzanna Rybka
University Clinical Center, Medical University of Warsaw, Warsaw, Poland
ORCID ID: 0009-0001-4056-8800

Julia Żak
Czerniakowski Hospital, Warsaw, Poland
ORCID ID: 0009-0008-3383-8025

Jakub Winiarczyk
Independent Public Health Care Complex in Pruszków, Pruszków, Poland
ORCID ID: 0009-0008-8163-5580

ABSTRACT

Background: Small intestinal bacterial overgrowth (SIBO) contributes significantly to the pathogenesis and symptom severity of irritable bowel syndrome (IBS). It is associated with microbial dysbiosis, abnormal intestinal gas fermentation, altered motility, and systemic metabolic and neurocognitive effects, including brain fogginess. Diagnostic uncertainty and lack of a universally accepted gold standard complicate clinical management.
Aim: This review synthesizes current evidence on disease mechanisms, diagnostic challenges, therapeutic strategies, and the impact on patient quality of life in SIBO-associated IBS.
Methods: A literature search was conducted in PubMed, Scopus, and Google Scholar for full-text articles published between 2000 and 2025. Clinical studies, systematic reviews, and meta-analyses addressing pathophysiology, diagnostics, and treatment outcomes were included.
Results: Microbial dysbiosis exacerbates gastrointestinal symptoms through excessive gas production and disrupted motility. Patients frequently report cognitive impairments, including brain fogginess, alongside gastrointestinal distress. Targeted therapy with nonabsorbable antibiotics provides significant symptom relief and improves functional capacity. Persistent diagnostic challenges underscore the need for standardized breath testing and microbial assessments to guide management.
Conclusion: Incorporating specific microbial diagnostics into routine gastroenterological practice is essential for optimizing treatment in SIBO-associated IBS. Recognizing the multifaceted impact of bacterial overgrowth enables clinicians to implement targeted therapies, address both intestinal and systemic consequences, and improve long-term patient outcomes.

KEYWORDS

SIBO, Irritable Bowel Syndrome, Treatment, Quality of Life, Bioengineering, Artificial Intelligence

CITATION

Karolina Dąbrowska, Emilia Lenkiewicz, Alicja Maciejewska, Monika Stępińska, Marta Omiecińska, Maja Kaczor, Weronika Trynkiewicz, Zuzanna Rybka, Julia Żak, Jakub Winiarczyk. (2026) The Role of Small Intestinal Bacterial Overgrowth in the Pathogenesis, Management and Quality of Life in Patients with Irritable Bowel Syndrome – A Literature Review. *International Journal of Innovative Technologies in Social Science*. 2(50). doi: 10.31435/ijitss.2(50).2026.5210

COPYRIGHT

© The author(s) 2026. This article is published as open access under the **Creative Commons Attribution 4.0 International License (CC BY 4.0)**, allowing the author to retain copyright. The CC BY 4.0 License permits the content to be copied, adapted, displayed, distributed, republished, or reused for any purpose, including adaptation and commercial use, as long as proper attribution is provided.

Introduction

Irritable Bowel Syndrome (IBS) is one of the most common of the Functional Gastrointestinal Disorders. IBS is defined as chronic/intermittent abdominal pain that may be associated with many alterations in bowel habits. There are no known structural causes for IBS. IBS has considerable implications for both healthcare and society as a whole. These include frequent doctor visits, decreased productivity at work, and decreased psychological well-being. While the true cause of IBS remains a mystery, researchers have developed several theories. Some of these include: 1) abnormal gut function (motility); 2) hypersensitivity to visceral stimuli; 3) inflammation; and 4) a relationship between the central nervous system (CNS) and the gastrointestinal tract (GIT), and/or a changed composition of the normal gut flora (the gut microbiome) (Pimentel et al., 2003). In recent years, research into the association of Small Intestinal Bacterial Overgrowth (SIBO) and symptoms experienced by individuals with IBS has been increasing. SIBO is identified by the presence of an increased number/distribution of bacteria present in the small intestine. When the normal ratio of bacteria in the small intestine is disrupted, the environment created can allow for the increased fermentation of food substrates resulting in gas, mucosal irritation and subsequent inflammatory response. Previous studies have indicated that the prevalence of SIBO in individuals experiencing symptoms of IBS is higher than in healthy control subjects. This creates the potential for SIBO to contribute to the pathophysiology of IBS (Shah et al., 2020). Clinical outcomes from SIBO may occur due to effects on intestinal permeability, motility, and immune function. Individuals who have IBS and SIBO have also demonstrated more severe gastrointestinal symptoms and lower quality of life scores than those with IBS alone (Chuah et al., 2023). Although evidence exists supporting the notion that SIBO may play a role in the symptoms experienced by individuals with IBS, discrepancies exist in the results of various studies making it difficult to conclude the diagnostic criteria and treatment options for

SIBO in the context of IBS. Thus, the objective of this literature review will be to examine existing literature that addresses the potential contribution of SIBO to symptomatology, management strategies, and quality of life in individuals diagnosed with IBS.

Materials and Methods

A literature search was conducted using the databases PubMed, Scopus, and Google Scholar to identify publications related to small intestinal bacterial overgrowth and irritable bowel syndrome. Studies published between 2000 and 2025 were included. The search was performed using combinations of keywords such as small intestinal bacterial overgrowth, SIBO, irritable bowel syndrome, pathogenesis, treatment, and quality of life. Additional relevant publications were identified through manual review of reference lists from selected articles.

Results

1.1 Pathogenesis of Irritable Bowel Syndrome

1.1.1 Motility Disorders

Altered gastrointestinal motility is frequently observed in patients with irritable bowel syndrome and contributes to symptom variability. Abnormal intestinal contractions may lead to accelerated or delayed transit, which corresponds with diarrhea dominant, constipation dominant, or mixed clinical forms (Camilleri, 2012; Chey et al., 2015). These disturbances result from interactions between the enteric nervous system, intestinal smooth muscle activity, and neurohumoral regulatory pathways. Dysregulation of serotonin signaling, which regulates intestinal secretion and peristalsis, has been associated with impaired motor responses in individuals with irritable bowel syndrome (Ford et al., 2017). Psychological stress may further influence bowel motility through altered autonomic nervous system activity (Mayer et al., 2014). Intestinal microbiota also plays a role in motility regulation through bacterial metabolites and gas production that affect intestinal transit. However, variability in motility findings suggests that these abnormalities alone cannot fully explain irritable bowel syndrome symptoms (Simrén et al., 2013; Camilleri et al., 2012).

1.1.2 Visceral Hypersensitivity

Visceral hypersensitivity is a major factor responsible for abdominal pain and discomfort in irritable bowel syndrome. It is characterized by increased sensitivity to intestinal stimuli and reduced pain thresholds during bowel distension (Ford et al., 2017). The development of this condition involves peripheral and central sensitization mechanisms. Peripheral sensitization is associated with low grade mucosal inflammation, increased intestinal permeability, and immune activation that enhance stimulation of sensory neural pathways (Bashashati et al., 2014). Elevated inflammatory mediators and immune cell infiltration have been reported in affected individuals, indicating immune involvement in sensory dysfunction (Ringel & Maharshak, 2013). Central sensitization involves altered processing of visceral signals within the brain, where psychological stress may intensify pain perception (Mayer et al., 2014). Additionally, disturbances in intestinal microbiota have been linked to increased sensory responses through their influence on immune activity and neural communication pathways (Simrén et al., 2013).

1.1.3 Brain-Gut Axis

The brain-gut axis represents a bidirectional communication network linking the central nervous system, the enteric nervous system, and the gastrointestinal tract. This regulatory system plays an important role in controlling intestinal motility, secretion, immune activity, and perception of visceral stimuli, all of which are frequently altered in irritable bowel syndrome (Mayer et al., 2014; Ford et al., 2017). Psychological stress may influence intestinal function through autonomic and neuroendocrine mechanisms, particularly through activation of the hypothalamic-pituitary-adrenal pathway, resulting in increased intestinal permeability and altered immune responses (Chey et al., 2015; Quigley, 2018). Functional neuroimaging studies have demonstrated abnormal central processing of visceral signals in affected individuals, indicating altered brain responses to intestinal stimulation (Mayer et al., 2014). Recent evidence highlights the role of intestinal microbiota as a key mediator of brain-gut communication. Microbial metabolites and inflammatory mediators may influence neuronal signaling, while central nervous system activity can simultaneously modify intestinal microbial composition. Disruption of these regulatory pathways is considered an important contributor to symptom development and persistence in irritable bowel syndrome (Simrén et al., 2013; Shrestha et al., 2022).

1.1.4 Immune Activation

Immune activation has become increasingly acknowledged as a major contributor to the pathogenesis of irritable bowel syndrome (IBS). While IBS does not represent an overtly inflamed condition, many reports suggest the presence of low-level or "subtle" immune alteration within the intestinal mucosa. Many patients will have elevated levels of various immune cells in their intestinal tissue, such as mast cells and lymphocytes. These cells could possibly disrupt normal gastrointestinal function through interference with sensory processing and motility regulation (Ringel & Maharshak, 2013). Histamine and proteolytic enzyme release from activated mast cells can activate enteric nerves and amplify visceral pain perception. In addition, several studies have demonstrated disturbances in cytokine balances; these include increases in pro-inflammatory cytokines and decreases in anti-inflammatory cytokines, suggesting an inability of the body's immune system to regulate itself properly (Bashashati et al., 2014). Immune changes can also occur as a result of gastrointestinal infection, providing support for the hypothesis that post-infectious IBS results from persistent immune and epithelial barrier dysfunction and altered motility, secretion, and enhanced visceral sensitivity (Ford et al., 2020).

1.1.5 Role of Microbiota

Intestinal microbiota is increasingly recognized as a key contributor to the pathogenesis of irritable bowel syndrome through its effects on immune activity, mucosal barrier function, and gastrointestinal regulation. The gastrointestinal tract contains a complex microbial community that supports metabolic processes, nutrient absorption, and protection against harmful microorganisms (Shrestha et al., 2022). In patients with irritable bowel syndrome, disturbances in microbial diversity and composition, often referred to as dysbiosis, are commonly identified and may correlate with clinical manifestations and disease subtypes (Saleem et al., 2025). Decreased populations of beneficial bacteria, including Bifidobacterium and Faecalibacterium, together with increased levels of potentially harmful microorganisms, may impair epithelial barrier integrity and stimulate immune responses that promote inflammation and sensory abnormalities (Saleem et al., 2025). Furthermore, bacterial metabolites such as short-chain fatty acids and bile acids can modulate intestinal motility and visceral perception, which may contribute to symptom development (Shrestha et al., 2022).

1.2 Small Intestinal Bacterial Overgrowth

1.2.1 Definition and Diagnostic Criteria

The definition of SIBO is inconsistent, resulting in inconsistencies in the diagnostic methods employed and the prevalence of SIBO. In the past, SIBO was diagnosed by the presence of at least 10^5 CFU/mL in a small bowel aspirate culture. This number, however, does not represent the entire spectrum of microbial diversity nor metabolism that exists in the small bowel. Historically, jejunal aspirate culture has been the gold standard for diagnosing SIBO; however, due to its invasive nature and limited sample size, it is impractical to use as a common clinical tool. As a result, glucose or lactulose breath tests have become the most frequently employed non-invasive diagnostic test for determining hydrogen or methane production as a consequence of bacterial fermentation. While these tests provide useful clinical data, they do vary significantly with regard to sensitivity and specificity. The absence of standardized diagnostic criteria continues to complicate the interpretation of clinical findings and comparison between studies evaluating the contribution of SIBO to IBS symptoms (Grace et al., 2013; Bohm et al., 2013; Quigley, 2019; Shah et al., 2020).

1.2.2 Epidemiology

Small intestinal bacterial overgrowth is increasingly recognized as a clinically relevant condition. However, its true prevalence remains difficult to determine because of substantial heterogeneity in diagnostic criteria and study methodologies. Available evidence suggests that SIBO may be detected in up to 20 percent of asymptomatic individuals, indicating that bacterial overgrowth can occur in the absence of overt clinical manifestations (Grace et al., 2013). The prevalence appears to increase with advancing age and is more frequently observed in individuals with disturbances in gastrointestinal motility, structural abnormalities of the intestine, or impaired immune regulation. In patients with irritable bowel syndrome, reported prevalence rates vary considerably, ranging from approximately 4 percent to 64 percent depending on the diagnostic approach, study population, and interpretation of breath testing results (Grace et al., 2013). Systematic reviews and meta-analytical data indicate a higher likelihood of bacterial overgrowth among individuals with IBS compared with healthy controls, supporting the concept that SIBO may contribute to symptom development and clinical variability within IBS populations. However, the direct comparison of reported prevalence estimates remains a challenge due to the methodological differences between studies, which continue to restrict precise epidemiological interpretation (Quigley, 2019).

1.2.3 Risk Factors

The development of small intestinal bacterial overgrowth is associated with clinical conditions that disrupt physiological mechanisms responsible for limiting microbial colonization within the small intestine. Impaired gastrointestinal motility represents one of the most significant risk factors, as coordinated peristalsis and migrating motor complexes normally prevent bacterial accumulation. Reduced intestinal clearance facilitates prolonged bacterial contact with mucosal surfaces and promotes microbial proliferation (Grace et al., 2013; Quigley, 2019; Shah et al., 2013).

Structural abnormalities, including diverticula, strictures, blind loops, and postsurgical anatomical changes, create areas of luminal stasis that favor bacterial colonization (Bohm et al., 2013; Grace et al., 2013). Reduced gastric acid secretion also contributes to bacterial survival within the upper gastrointestinal tract, and long-term acid-suppressive therapy has been associated with increased risk of bacterial overgrowth. Additionally, chronic liver disease, pancreatitis, immune deficiencies, and inflammatory bowel disease may impair mucosal defense and barrier function, further increasing susceptibility to SIBO and potentially intensifying gastrointestinal symptom development (Grace et al., 2013; Shah et al., 2013).

1.2.4 Pathophysiological Mechanisms

Small intestinal bacterial overgrowth develops when physiological mechanisms regulating microbial balance become disrupted, allowing excessive bacterial proliferation and alterations in microbial composition. Impaired gastric acidity, reduced digestive secretions, and ineffective intestinal motility facilitate bacterial persistence within the small intestine (Grace et al., 2013; Bohm et al., 2013; Quigley, 2019). Structural abnormalities may further enhance luminal stasis and promote colonization. Bacterial overgrowth contributes to symptom generation through metabolic, inflammatory, and barrier related mechanisms. Excessive fermentation increases production of hydrogen, methane, and other gases, leading to intestinal distension and altered bowel patterns. Microbial metabolism may disrupt bile acid homeostasis and nutrient absorption while damaging epithelial integrity. Furthermore, bacterial metabolites and toxins may increase intestinal permeability and stimulate immune activation, which enhances mucosal inflammation and sensory signaling. These processes may intensify abdominal pain, bloating, and bowel habit disturbances characteristic of IBS, supporting the role of SIBO as a potential driver of symptom expression (Grace et al., 2013; Shah et al., 2020).

1.3 Relationship Between SIBO and IBS

1.3.1 Prevalence of SIBO in IBS

Establishing a definitive prevalence rate for SIBO within the IBS population is complicated by the absence of a universally recognized diagnostic gold standard (Rezaie et al., 2017). According to a significant meta-analysis, the pooled prevalence of SIBO in IBS patients stands at approximately 38%, suggesting that individuals with this functional disorder have a nearly fivefold higher risk of bacterial overgrowth compared to healthy cohorts (Chen et al. 2018). These observations are supported by earlier research, which identified a prevalence of 31% specifically through glucose breath testing, though it noted that results vary significantly based on the substrate employed (Ford et al. 2009). Discrepancies in reported data are frequently attributed to geographical variations, diverse patient selection criteria, and the specific diagnostic cut-offs utilized across different clinical trials (Marginean et al., 2024). Although the introduction of the North American Consensus guidelines (Rezaie et al., 2017) sought to harmonize testing protocols, reported incidence rates in the literature still range widely, from 4% to over 70% (Shah et al., 2020). Nevertheless, the consistently high frequency of SIBO, particularly in diarrhea-predominant IBS, reinforces the necessity of considering bacterial overgrowth as a key clinical factor in IBS management (Quigley, 2019).

1.3.2 Shared Pathophysiological Mechanisms

The mechanistic overlap between SIBO and IBS is primarily rooted in the impairment of the migrating motor complex (MMC) and the subsequent development of visceral hypersensitivity. A deficient phase III of the MMC fails to provide the necessary propulsive force to clear residual bacteria and debris from the small intestine, creating a biological niche for microbial proliferation (Takakura & Pimentel, 2020). Central to this process is the exposure to cytolethal distending toxin B (CdtB) following acute enteric infections, which may trigger the production of anti-vinculin antibodies (Pimentel et al., 2015). These antibodies engage in molecular mimicry with neuronal proteins within the enteric nervous system, leading to the sustained dysmotility often observed in post-infectious IBS phenotypes and contributing to SIBO susceptibility. Additionally, the expanded bacterial population disrupts intestinal homeostasis through bile acid deconjugation and increased production of gaseous metabolites, contributing to epithelial dysfunction and altered intestinal permeability (Ghoshal et al., 2017). The resulting translocation of microbial antigens induces a state of low-grade mucosal

inflammation that lowers the threshold for pain by sensitizing peripheral afferent nerves. Ultimately, these shared pathways suggest a bidirectional relationship where motor dysfunction facilitates dysbiosis, while microbial byproducts reinforce the sensory and structural abnormalities characteristic of IBS.

1.3.3 Role of Gas Production and Fermentation

The physiological impact of SIBO on IBS patients is largely mediated by the metabolic processing of malabsorbed carbohydrates, which leads to an abnormal accumulation of gaseous byproducts within the small intestine. This fermentation precipitates intraluminal distension, activating mechanoreceptors that, in the presence of underlying visceral hypersensitivity, translate into significant abdominal pain and bloating (Quigley, 2019). The clinical phenotype observed is highly dependent on the predominant gas produced during this microbial activity. While hydrogen is a standard byproduct of fermentation associated with general discomfort, methane acts as a gaseous neuromodulator that significantly reduces intestinal motility, thereby correlating with constipation-predominant IBS (Pimentel et al., 2006). Furthermore, emerging evidence identifies hydrogen sulfide as a critical factor in diarrhea-predominant cases, as it may increase epithelial permeability and irritate the mucosal lining (Takakura & Pimentel, 2020). Consequently, the complex relationship between these fermentation products and the enteric nervous system determines the range and severity of symptoms in SIBO and IBS.

1.3.4 Diagnostic Challenges

Diagnosing SIBO in individuals suffering from IBS remains an ongoing problem primarily because current diagnostic methods are limited. As a result of these limitations, the traditional "gold-standard" method of diagnosing SIBO using quantitative jejunal aspirate culture has very real drawbacks. Due to the invasiveness of this technique, the associated costs of performing the test, and the possibility of contamination by oropharyngeal flora (Khoshini et al., 2008), it is rarely used in clinical practice. Furthermore, standard culture techniques often fail to account for obligate anaerobes that reside in the distal small intestine. Consequently, non-invasive hydrogen and methane breath tests have emerged as the primary diagnostic tools in clinical practice, yet they are frequently criticized for their suboptimal sensitivity and specificity (Ghoshal, 2011). Discrepancies in substrate selection, such as the use of glucose versus lactulose, frequently lead to inconsistent results, with glucose being more specific but potentially failing to detect overgrowth in the distal ileum (Ford et al., 2009). These diagnostic uncertainties complicate the establishment of a definitive causal link between SIBO and IBS symptoms, necessitating a more standardized approach to breath testing interpretation (Rezaie et al., 2017).

1.3.5 Emerging Diagnostic Technologies

To overcome the existing flaws of indirect breath testing, modern bioengineering offers unprecedented precision through smart clinical devices. Novel ingestible electronic capsules now permit continuous profiling of intraluminal gases directly within the human gut. Instead of relying on exhaled samples, these ingestible sensors measure hydrogen, oxygen, and methane at the exact site of bacterial fermentation. This creates a highly accurate spatial map of microbial activity in real time, completely bypassing the uncertainties of transit variations (Kalantar-Zadeh et al., 2018). Concurrently, the integration of artificial intelligence into capsule endoscopy is transforming structural intestinal assessments. Deep learning algorithms can autonomously evaluate thousands of captured mucosal images to identify subtle inflammatory signs, villous atrophy, or fluid pooling linked to microbial proliferation that human reviewers often overlook (Xie et al., 2022). By combining this direct metabolic monitoring with advanced computer vision, gastroenterologists may soon eliminate the need for traditional invasive cultures entirely. Such precision tools promise to redefine standard clinical guidelines, finally ensuring accurate targeted therapies for individuals suffering from severe functional bowel symptoms (Dray et al., 2021).

1.4 Management of SIBO in IBS

1.4.1 Pharmacological Treatment

Pharmacotherapy for SIBO-IBS focuses on eradicating bacterial overgrowth and maintaining remission through prokinetic support. Randomized clinical trials have demonstrated that rifaximin significantly improves global gastrointestinal symptoms and reduces bloating compared with placebo (Pimentel et al., 2011). Nevertheless, the therapeutic strategy must be adjusted when methane is detected, as this gas is directly linked to constipation and slowed intestinal transit (Pimentel et al., 2006). Research indicates that methane-positive patients achieve significantly higher success rates when treated with a combination of rifaximin and neomycin compared to antibiotic monotherapy (Pimentel et al., 2014). To prevent the high rate of relapse associated with migrating motor complex (MMC) dysfunction, the use of nocturnal prokinetics is recommended. Low doses of erythromycin or tegaserod have proven effective in stimulating small bowel motility, thereby delaying the return of symptoms (Pimentel et al., 2009).

1.4.2 Dietary Therapy

Dietary interventions serve as a critical therapeutic strategy in the management of SIBO and IBS by reducing the substrates available for bacterial fermentation. The low-FODMAP diet is the most established nutritional approach, focusing on the restriction of poorly absorbed short-chain carbohydrates that are rapidly fermented by enteric flora (Gibson & Shepherd, 2010). By limiting the intake of oligosaccharides, disaccharides, monosaccharides, and polyols, this protocol minimizes luminal distension and significantly alleviates functional gastrointestinal symptoms. For patients requiring a more aggressive eradication strategy or those intolerant to antibiotics, the elemental diet offers a convincing alternative. Pimentel et al. (2004) demonstrated that a 14-day exclusive liquid elemental diet normalized lactulose breath tests in up to 85% of subjects. This formulation is completely assimilated in the proximal small intestine, thereby depriving bacteria in the distal bowel of essential nutrients and effectively reducing the microbial load (Pimentel et al., 2004).

1.4.3 Probiotics and Microbiota Modulation

The role of probiotics in managing SIBO remains a subject of significant debate within the clinical community. Meta-analyses indicate that probiotic supplementation may effectively reduce hydrogen concentrations and achieve a decontamination rate of approximately 63% (Zhong et al., 2017). These beneficial microorganisms are thought to enhance mucosal integrity and outcompete pathogenic bacteria for resources. However, some researchers express caution regarding the introduction of additional bacteria into an already colonized small bowel, noting that this might exacerbate gas production or contribute to metabolic complications like brain fogginess (Quigley, 2019). Beyond probiotics, more advanced methods of microbiota modulation are emerging. Recent clinical trials demonstrate that fecal microbiota transplantation can successfully reestablish microbial diversity and alleviate gastrointestinal symptoms in patients who do not respond to traditional treatments (Xu et al., 2019). These findings suggest that personalized approaches to restoring eubiosis are essential for long-term recovery in SIBO-IBS cases.

1.5 Impact of SIBO on Quality of Life

1.5.1 Symptom Severity

The presence of small intestinal bacterial overgrowth significantly amplifies the clinical burden in patients diagnosed with irritable bowel syndrome. Clinical evaluations indicate that individuals with overlapping SIBO frequently report pronounced abdominal pain, severe bloating, and generalized gastrointestinal discomfort (Moraru et al., 2014; Shah et al., 2020). The profile of excessive gas production further influences bowel habit patterns. The degree of methane production correlates with increased stool hardness and constipation severity (Pimentel et al., 2006), whereas hydrogen predominance is more commonly associated with diarrheal phenotypes and accelerated intestinal transit (Pimentel et al., 2006). The clinical relevance of microbial imbalance is further supported by interventional trials demonstrating that eradication therapy with targeted nonabsorbable antibiotics results in significant reductions in global symptom scores and abdominal distress (Pimentel et al., 2011).

1.5.2 Psychological Consequences

Research regarding the gut-brain axis indicates that microbial dysbiosis correlates with physiological changes outside the gastrointestinal tract (Osadchiy et al., 2019). Clinical observations link altered intestinal profiles to systemic inflammatory responses and modifications in neurotransmitter synthesis. These biological shifts are associated with increased rates of anxiety and depressive disorders among affected cohorts (Rao & Tan, 2021). Furthermore, a subset of patients exhibits neurocognitive symptoms categorized as brain fog, which includes documented impairments in mental clarity and working memory (Rao et al., 2018). Laboratory

findings identify the systemic accumulation of the D-isomer of lactic acid as a primary metabolic marker for these deficits. This compound is produced during the microbial fermentation of carbohydrates within the small intestine (Rao et al., 2018). Data also indicate that probiotic consumption in certain subjects correlates with elevated D-lactate levels and a subsequent increase in cognitive dysfunction (Rao et al., 2018).

1.5.3 Social and Economic Impact

Quantitative analyses indicate that small intestinal bacterial overgrowth and related functional gastrointestinal disorders impose a substantial economic burden on healthcare systems. Direct costs are largely driven by medical consultations, diagnostic procedures, and pharmacological interventions, including courses of nonabsorbable antibiotics. Indirect costs include reduced labor productivity, with affected individuals frequently reporting absenteeism and presenteeism. Activity impairment assessments further demonstrate that patients with these conditions have a diminished capacity for professional and social tasks compared to healthy populations (Canavan et al., 2014; Frändemark et al., 2018). Collectively, these factors contribute to a cumulative financial impact comparable to that observed in other chronic gastrointestinal disorders, reflecting both increased healthcare resource utilization and decreased overall workforce productivity.

Discussion

Clinical Implications

The findings from this review carry direct consequences for routine gastroenterological practice. Clinicians should consider small intestinal bacterial overgrowth as a primary differential diagnosis in patients presenting with refractory irritable bowel syndrome. Because the overlap of these conditions is associated with increased abdominal distress and cognitive symptoms, such as brain fogginess, which have been observed clinically in patients with SIBO (Rao et al., 2018), early detection becomes critical. Diagnostic protocols need an update. Medical professionals must prioritize validated breath tests or duodenal cultures before initiating any pharmacological interventions (Shah et al., 2013). Blindly prescribing broad-spectrum antibiotics or unguided probiotic supplements might actually worsen underlying dysbiosis and metabolic acidosis. Instead, targeted eradication strategies utilizing nonabsorbable antibiotics demonstrate high clinical efficacy in alleviating both intestinal and systemic symptoms (Pimentel et al., 2011). Ultimately, integrating specific microbial assessments into standard care pathways will prevent unnecessary procedures and significantly improve long-term patient outcomes.

Strengths and Limitations

A major strength of this review involves the comprehensive synthesis of current literature detailing both hydrogen and methane profiles in bacterial overgrowth. This approach provides a highly detailed perspective on how specific microbial gases dictate clinical phenotypes in functional gastrointestinal disorders. Several methodological constraints still require acknowledgment. The primary limitation stems from the high heterogeneity among the evaluated source studies. Most available clinical trials rely on relatively small sample sizes and employ diverse patient selection criteria. The medical community also lacks a universally accepted gold standard for diagnosing this condition. Discrepancies between glucose and lactulose breath tests frequently complicate data interpretation and skew reported prevalence rates (Ford et al., 2009). Variations in diagnostic cutoff values across different regions make it difficult to establish definitive global epidemiological trends (Rezaie et al., 2017). Despite these analytical challenges, the synthesized evidence consistently confirms a strong pathogenic link, validating our main clinical conclusions.

Comparison With Previous Studies

Our findings regarding the high prevalence of bacterial overgrowth align perfectly with major previous analyses. Chen et al. (2018) established an overall pooled prevalence of nearly 38 percent in affected patient cohorts. Early reviews also highlighted that diagnostic yield heavily depends on the chosen breath test substrate (Ford et al. 2009). Regarding specific gas profiles, the reviewed literature supports meta-analytic evidence indicating that methane production is associated with delayed intestinal transit and severe constipation (Kunkel et al., 2011). This current review expands upon traditional paradigms discussed by Quigley (2018). We place a much stronger emphasis on the neurocognitive consequences of microbial dysbiosis, specifically brain fogginess and metabolic acidosis, moving beyond standard gastrointestinal symptoms to highlight the broader systemic impact.

Future Research Directions

Future investigations must prioritize the establishment of a universally accepted gold standard for diagnosing small intestinal bacterial overgrowth. Current discrepancies regarding breath test substrates severely limit epidemiological accuracy across diverse clinical cohorts (Ford et al., 2009). Researchers should focus on standardizing diagnostic protocols to ensure highly reliable patient data. Beyond basic diagnostics, the medical community requires large scale randomized controlled trials to properly evaluate the long term efficacy of targeted eradication therapies. Future studies must also evolve beyond traditional duodenal aspirate cultures. Implementing advanced microbial sequencing techniques will help scientists fully elucidate the complex pathogenic mechanisms within the small bowel (Quigley, 2018). Finally, longitudinal tracking of systemic metabolic byproducts is essential to map the exact pathways causing cognitive impairments. Addressing these specific knowledge gaps will directly optimize future therapeutic interventions.

Conclusions

This literature review confirms that small intestinal bacterial overgrowth represents a significant clinical factor in the pathogenesis and symptom severity of irritable bowel syndrome. Systematic evidence demonstrates that microbial dysbiosis does not function as an isolated gastrointestinal issue but rather triggers systemic inflammatory and metabolic responses. These processes directly contribute to both physical distress and neurocognitive impairments such as brain fogginess (Rao et al., 2018). While prevalence rates vary because of inconsistent diagnostic standards, studies of functional gastrointestinal disorders consistently show a correlation between positive breath tests and diminished quality of life in affected cohorts (Frändemark et al., 2018). Improving patient outcomes requires a transition toward more precise diagnostic protocols and targeted antibiotic therapies. In the final analysis, the recognition of the multifaceted effects of bacterial overgrowth enables the development of more effective management strategies that address the intestinal and psychological aspects of this complex disorder.

Authors' contribution:

Conceptualization: Karolina Dąbrowska

Methodology: Emilia Lenkiewicz, Alicja Maciejewska, Monika Stepinska

Investigation: Marta Omiecińska, Maja Kaczor

Resources: Weronika Trynkiewicz, Zuzanna Rybka

Data curation/ Check: Julia Żak, Jakub Winiarczyk

Writing-original draft preparation: Emilia Lenkiewicz, Alicja Maciejewska, Monika Stepinska, Marta Omiecińska, Maja Kaczor, Weronika Trynkiewicz, Zuzanna Rybka, Julia Żak

Writing-review and editing: Karolina Dąbrowska, Marta Omiecińska, Maja Kaczor, Julia Żak, Emilia Lenkiewicz, Alicja Maciejewska, Monika Stepinska, Zuzanna Rybka

Supervision: Karolina Dąbrowska

Visualization: Maja Kaczor, Monika Stepinska

All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding

Data availability statement: Data sharing is not applicable to this article

Conflict of interest: The authors declare no conflict of interest

Declaration of the use of generative AI and AI-assisted technologies in the writing process: In preparing this work, the authors used generative AI tools (ChatGPT) solely to support language editing and text formatting. After using these tools, the authors reviewed and edited the text as needed and accepted full responsibility for the content of the publication.

REFERENCES

1. Bashashati, M., Rezaei, N., Shafieyoun, A., McKernan, D. P., Chang, L., Öhman, L., Quigley, E. M. M., Schmulson, M., Sharkey, K. A., & Simrén, M. (2014). Cytokine imbalance in irritable bowel syndrome: A systematic review and meta-analysis. *Neurogastroenterology & Motility, 26*(7), 1036–1048. https://doi.org/10.1111/nmo.12358
2. Böhm, M., Siwiec, R. M., & Wo, J. M. (2013). Diagnosis and management of small intestinal bacterial overgrowth. *Nutrition in Clinical Practice, 28*(3), 289–299. https://doi.org/10.1177/0884533613485882
3. Camilleri, M. (2012). Peripheral mechanisms in irritable bowel syndrome. *New England Journal of Medicine, 367*(17), 1626–1635. https://doi.org/10.1056/NEJMra1207068
4. Canavan, C., West, J., & Card, T. (2014). Review article: The economic impact of irritable bowel syndrome. *Alimentary Pharmacology & Therapeutics, 40*(9), 1023–1034. https://doi.org/10.1111/apt.12938
5. Chen, B., Kim, J. J., Zhang, Y., Du, L., & Chen, X. (2018). Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: A systematic review and meta-analysis. *Journal of Gastroenterology, 53*(7), 807–818. https://doi.org/10.1007/s00535-018-1476-9
6. Chey, W. D., Kurlander, J., & Eswaran, S. (2015). Irritable bowel syndrome: A clinical review. *JAMA, 313*(9), 949–958. https://doi.org/10.1001/jama.2015.0954
7. Chuah, K. H., Hian, W. X., Lim, S. Z., Beh, K. H., & Mahadeva, S. (2023). Impact of small intestinal bacterial overgrowth on symptoms and quality of life in irritable bowel syndrome. *Journal of Digestive Diseases, 24*(3), 194–202. https://doi.org/10.1111/1751-2980.13189
8. Dray, X., Iakovidis, D., Houdeville, C., Jover, R., Diamantis, D., Histace, A., & Koulaouzidis, A. (2021). Artificial intelligence in small bowel capsule endoscopy: Current status, challenges and future promise. *Journal of Gastroenterology and Hepatology, 36*(1), 12–19. https://doi.org/10.1111/jgh.15341
9. Ford, A. C., Lacy, B. E., & Talley, N. J. (2017). Irritable bowel syndrome. *New England Journal of Medicine, 376*(26), 2566–2578. https://doi.org/10.1056/NEJMra1607547
10. Ford, A. C., Lacy, B. E., & Talley, N. J. (2017). Irritable bowel syndrome. *The Lancet, 391*(10122), 1675–1688. https://doi.org/10.1016/S0140-6736(20)31548-8
11. Ford, A. C., Spiegel, B. M. R., Talley, N. J., & Moayyedi, P. (2009). Small intestinal bacterial overgrowth in irritable bowel syndrome: Systematic review and meta-analysis. *Clinical Gastroenterology and Hepatology, 7*(12), 1279–1286. https://doi.org/10.1016/j.cgh.2009.06.031
12. Frändemark, Å., Törnblom, H., Jakobsson, S., & Simrén, M. (2018). Work productivity and activity impairment in irritable bowel syndrome (IBS): A multifaceted problem. *The American Journal of Gastroenterology, 113*(10), 1540–1549. https://doi.org/10.1038/s41395-018-0262-x
13. Ghoshal, U. C. (2011). How to interpret hydrogen breath tests. *Journal of Neurogastroenterology and Motility, 17*(3), 312–317. https://doi.org/10.5056/jnm.2011.17.3.312
14. Ghoshal, U. C., Shukla, R., & Ghoshal, U. (2017). Small intestinal bacterial overgrowth and irritable bowel syndrome: A bridge between functional organic dichotomy. *Gut and Liver, 11*(2), 196–208. https://doi.org/10.5009/gnl16126
15. Gibson, P. R., & Shepherd, S. J. (2010). Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach. *Journal of Gastroenterology and Hepatology, 25*(2), 252–258. https://doi.org/10.1111/j.1440-1746.2009.06149.x
16. Grace, E., Shaw, C., Whelan, K., & Andreyev, H. J. N. (2013). Small intestinal bacterial overgrowth: Prevalence, clinical features, current and developing diagnostic tests, and treatment. *Alimentary Pharmacology & Therapeutics, 38*(7), 674–688. https://doi.org/10.1111/apt.12456
17. Kalantar-Zadeh, K., Berean, K. J., Ha, N., Chrimes, A. F., Xu, K., Grando, D., Ou, J. Z., Pillai, N., Campbell, J. L., Brkljača, R., Taylor, K. J., Wang, R. E., Yao, C. K., Ward, S. A., McSweeney, C. S., Muir, J. G., & Gibson, P. R. (2018). A human pilot trial of ingestible electronic capsules capable of sensing different gases in the gut. *Nature Electronics, 1*(1), 79–87. https://doi.org/10.1038/s41928-017-0004-x
18. Khoshini, R., Dai, S. C., Lezcano, S., & Pimentel, M. (2008). A systematic review of diagnostic tests for small intestinal bacterial overgrowth. *Digestive Diseases and Sciences, 53*(6), 1443–1454. https://doi.org/10.1007/s10620-007-0065-1
19. Kunkel, D., Basseri, R. J., Makhani, M. D., Chong, K., Chang, C., & Pimentel, M. (2011). Methane on breath testing is associated with constipation: A systematic review and meta-analysis. *Digestive Diseases and Sciences, 56*(6), 1612–1618. https://doi.org/10.1007/s10620-011-1590-5
20. Mărginean, C. O., Meliț, L. E., & Săsăran, M. O. (2024). The relationship between small intestinal bacterial overgrowth and constipation in children: A comprehensive review. *Frontiers in Cellular and Infection Microbiology, 14*, Article 1431660. https://doi.org/10.3389/fcimb.2024.1431660
21. Mayer, E. A., Gupta, A., & Kilpatrick, L. A. (2014). Brain-gut-microbiome interactions in irritable bowel syndrome. *Gastroenterology, 146*(6), 1500–1512. https://doi.org/10.1053/j.gastro.2014.02.037
22. Mayer, E. A., Tillisch, K., & Gupta, A. (2015). Gut/brain axis and the microbiota. *Journal of Clinical Investigation, 125*(3), 926–938. https://doi.org/10.1172/JCI76304

23. Osadchiy, V., Martin, C. R., & Mayer, E. A. (2019). The gut-brain axis and the microbiome: Mechanisms and clinical implications. *Clinical Gastroenterology and Hepatology, 17*(2), 322–332. https://doi.org/10.1016/j.cgh.2018.10.002
24. Pimentel, M., Chow, E. J., & Lin, H. C. (2000). Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. *American Journal of Gastroenterology, 95*(12), 3503–3506. https://doi.org/10.1111/j.1572-0241.2000.03368.x
25. Pimentel, M., Constantino, T., Kong, Y., Bajwa, M., Rezaei, A., & Park, S. (2004). A 14-day elemental diet is highly effective in normalizing the lactulose breath test. *Digestive Diseases and Sciences, 49*(1), 73–77. https://doi.org/10.1023/B:DDAS.0000011605.43979.el
26. Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011). Rifaximin therapy for patients with irritable bowel syndrome without constipation. *The New England Journal of Medicine, 364*(1), 22–32. https://doi.org/10.1056/NEJMoa1004409
27. Pimentel, M., Lin, H. C., Enayati, P., van den Burg, B., Lee, H. R., Chen, J. H., Park, S., Kong, Y., Conklin, J., & Soffer, E. E. (2006). Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. *The American Journal of Physiology-Gastrointestinal and Liver Physiology, 290*(6), G1089–G1095. https://doi.org/10.1152/ajpgi.00574.2004
28. Pimentel, M., Low, K., Hwang, L., Hua, J., Zhu, A., & Morales, W. (2010). A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. *Journal of Clinical Gastroenterology, 44*(8), 547–550. https://doi.org/10.1097/MCG.0b013e3181c64c90
29. Pimentel, M., Morales, W., Lezcano, S., Sun-Chuan, D., Low, K., & Yang, J. (2009). Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. *Gastroenterology & Hepatology, 5*(6), 435–442. https://pubmed.ncbi.nlm.nih.gov/20574504/
30. Pimentel, M., Morales, W., Rezaie, A., Marsh, E., Lembo, A., Mirocha, J., Leffler, D. A., Shao, Z., Choung, R. S., Wouters, E., Talley, N. J., & Chang, C. (2015). Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome. *PLOS ONE, 10*(5), Article e0126438. https://doi.org/10.1371/journal.pone.0126438
31. Quigley, E. M. M. (2018). The gut-brain axis and the microbiome: Clues to pathophysiology and opportunities for novel management strategies in irritable bowel syndrome. *Journal of Clinical Medicine, 7*(1), Article 6. https://doi.org/10.3390/jcm7010006
32. Quigley, E. M. M. (2019). The spectrum of small intestinal bacterial overgrowth (SIBO). *Current Gastroenterology Reports, 21*(1), Article 3. https://doi.org/10.1007/s11894-019-0671-z
33. Rao, S. S. C., & Bhagatwala, J. (2019). Small intestinal bacterial overgrowth: Clinical features and therapeutic strategies. *Clinical and Translational Gastroenterology, 10*(10), Article e00078. https://doi.org/10.14309/ctg.0000000000000078
34. Rao, S. S. C., Rehman, A., Yu, S., & de Andino, N. M. (2018). Brain fogginess, gas and bloating: A link between small intestinal bacterial overgrowth, probiotics and metabolic acidosis. *Clinical and Translational Gastroenterology, 9*(6), Article e162. https://doi.org/10.1038/s41424-018-0030-7
35. Rezaie, A., Buresi, M., Lembo, A., Lin, H., McCallum, R., Rao, S., Schmulson, M., Valdovinos, M., Zakko, S., & Pimentel, M. (2017). Hydrogen and methane-based breath testing in gastrointestinal disorders: The North American Consensus. *The American Journal of Gastroenterology, 112*(5), 775–784. https://doi.org/10.1038/ajg.2017.46
36. Ringel, Y., & Maharshak, N. (2013). Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. *American Journal of Physiology-Gastrointestinal and Liver Physiology, 305*(8), G529–G541. https://doi.org/10.1152/ajpgi.00207.2012
37. Saleem, M. M., Masood, S., Rahmatullah, M. M., Imdad, I. A., Sange, A. M. A., & Nasr, D. (2025). Gut microbiota dysbiosis and its role in the development of irritable bowel syndrome. *Cureus, 17*(4), Article e83084. https://doi.org/10.7759/cureus.83084
38. Shah, A., Talley, N. J., Jones, M., Kendall, B. J., Koloski, N., Walker, M. M., Morrison, M., & Holtmann, G. J. (2020). Small intestinal bacterial overgrowth in irritable bowel syndrome: A systematic review and meta-analysis of case-control studies. *The American Journal of Gastroenterology, 115*(2), 190–201. https://doi.org/10.14309/ajg.0000000000000504
39. Shah, S. C., Day, L. W., Somsouk, M., & Sewell, J. L. (2013). Meta-analysis: Antibiotic therapy for small intestinal bacterial overgrowth. *Alimentary Pharmacology & Therapeutics, 38*(8), 925–934. https://doi.org/10.1111/apt.12479
40. Shrestha, B., Patel, D., Shah, H., Hanna, K. S., Kaur, H., Alazzeh, M. S., Thandavaram, A., Channar, A., Purohit, A., & Venugopal, S. (2022). The role of gut microbiota in the pathophysiology and therapy of irritable bowel syndrome: A systematic review. *Cureus, 14*(8), Article e28064. https://doi.org/10.7759/cureus.28064
41. Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M. R., Spiller, R. C., Vanner, S., Verdu, E. F., Whorwell, P. J., & Zoetendal, E. G. (2013). Intestinal microbiota in functional bowel disorders: A Rome Foundation report. *Gastroenterology, 144*(5), 1180–1191. https://doi.org/10.1136/gutjnl-2012-302167
42. So, D., Quigley, E. M. M., & Whelan, K. (2023). Probiotics in irritable bowel syndrome and inflammatory bowel disease: Review of mechanisms and effectiveness. *Current Opinion in Gastroenterology, 39*(2), 103–109. https://doi.org/10.1097/MOG.0000000000000902

43. Takakura, W., & Pimentel, M. (2020). Small intestinal bacterial overgrowth and irritable bowel syndrome: An update on pathophysiology, diagnosis, and treatment. *Frontiers in Psychiatry, 11*, Article 664. https://doi.org/10.3389/fpsyt.2020.00664
44. Xie, X., Chen, Y. Y., Zhong, T. T., et al. (2022). Development and validation of an artificial intelligence model for small bowel capsule endoscopy video review. *JAMA Network Open, 5*(7), Article e2221992. https://doi.org/10.1001/jamanetworkopen.2022.21992
45. Xu, D., Chen, V. L., Steiner, C. A., Berinstein, J. A., Eswaran, S., Waljee, A. K., Higgins, P. D. R., & Owyang, C. (2019). Efficacy of fecal microbiota transplantation in irritable bowel syndrome: A systematic review and meta-analysis. *The American Journal of Gastroenterology, 114*(7), 1043–1050. https://doi.org/10.14309/ajg.0000000000000198
46. Zhong, C., Qu, C., Wang, B., Liang, S., & Zeng, B. (2017). Probiotics for preventing and treating small intestinal bacterial overgrowth: A meta-analysis and systematic review of current evidence. *Journal of Clinical Gastroenterology, 51*(4), 300–311. https://doi.org/10.1097/MCG.0000000000000814